A phase II trial of sorafenib in metastatic melanoma with tissue correlates

Patrick A Ott, Anne Hamilton, Christina Min, Sara Safarzadeh-Amiri, Lauren Goldberg, Joanne Yoon, Herman Yee, Michael Buckley, Paul J Christos, John J Wright, David Polsky, Iman Osman, Leonard Liebes, Anna C Pavlick, Patrick A Ott, Anne Hamilton, Christina Min, Sara Safarzadeh-Amiri, Lauren Goldberg, Joanne Yoon, Herman Yee, Michael Buckley, Paul J Christos, John J Wright, David Polsky, Iman Osman, Leonard Liebes, Anna C Pavlick

Abstract

Background: Sorafenib monotherapy in patients with metastatic melanoma was explored in this multi-institutional phase II study. In correlative studies the impact of sorafenib on cyclin D1 and Ki67 was assessed.

Methodology/principal findings: Thirty-six patients treatment-naïve advanced melanoma patients received sorafenib 400 mg p.o. twice daily continuously. Tumor BRAF(V600E) mutational status was determined by routine DNA sequencing and mutation-specific PCR (MSPCR). Immunohistochemistry (IHC) staining for cyclin D1 and Ki67 was performed on available pre- and post treatment tumor samples. The main toxicities included diarrhea, alopecia, rash, mucositis, nausea, hand-foot syndrome, and intestinal perforation. One patient had a RECIST partial response (PR) lasting 175 days. Three patients experienced stable disease (SD) with a mean duration of 37 weeks. Routine BRAF(V600E) sequencing yielded 27 wild-type (wt) and 6 mutant tumors, whereas MSPCR identified 12 wt and 18 mutant tumors. No correlation was seen between BRAF(V600E) mutational status and clinical activity. No significant changes in expression of cyclin D1 or Ki67 with sorafenib treatment were demonstrable in the 15 patients with pre-and post-treatment tumor samples.

Conclusions/significance: Sorafenib monotherapy has limited activity in advanced melanoma patients. BRAF(V600E) mutational status of the tumor was not associated with clinical activity and no significant effect of sorafenib on cyclin D1 or Ki67 was seen, suggesting that sorafenib is not an effective BRAF inhibitor or that additional signaling pathways are equally important in the patients who benefit from sorafenib.

Trial registration: Clinical Trials.gov NCT00119249.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Kaplan-Meier analysis of progression-free survival.
Figure 1. Kaplan-Meier analysis of progression-free survival.
Figure 2. Cyclin D1 and Ki67 expression…
Figure 2. Cyclin D1 and Ki67 expression in tumor biopsies obtained before and after treatment with sorafenib.
A: Increase/decrease in the percentage of tumor cells staining for cyclin D1 and Ki67 between pre-treatment (day 1) and post-treatment (day 28) samples, as measured by immunohistochemistry. The numbers represent absolute changes in percentage of cells. B: Representative stainings for cyclin D1 and Ki67 from patient #20 are shown (40×).

References

    1. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24:4738–4745.
    1. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–2751.
    1. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158–166.
    1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954.
    1. Dong J, Phelps RG, Qiao R, Yao S, Benard O, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003;63:3883–3885.
    1. Gorden A, Osman I, Gai W, He D, Huang W, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 2003;63:3955–3957.
    1. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–1677.
    1. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003;63:5198–5202.
    1. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, et al. B-RAF is a therapeutic target in melanoma. Oncogene. 2004;23:6292–6298.
    1. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res. 2008;6:751–759.
    1. Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 2006;66:999–1006.
    1. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98:326–334.
    1. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109.
    1. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134.
    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
    1. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 2005;65:2412–2421.
    1. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95:581–586.
    1. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008;26:2178–2185.
    1. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27:2823–2830.
    1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216.
    1. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:527–534.
    1. Yancovitz M, Yoon J, Mikhail M, Gai W, Shapiro RL, et al. Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn. 2007;9:178–183.
    1. Albino AP, Juan G, Traganos F, Reinhart L, Connolly J, et al. Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation. Cancer Res. 2000;60:4139–4145.
    1. Tsai J, Lee JT, Wang W, Zhang J, Cho H, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008;105:3041–3046.
    1. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–819.
    1. Jilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, et al. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res. 2009;15:1076–1085.
    1. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–4346.
    1. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–2147.
    1. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26:2046–2051.
    1. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res. 2008;21:492–493.
    1. Handolias D, Hamilton AL, Salemi R, Tan A, Moodie K, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer. 2010;102:1219–1223.
    1. Karreth FA, DeNicola GM, Winter SP, Tuveson DA. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Mol Cell. 2009;36:477–486.
    1. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464:431–435.
    1. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427–430.
    1. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res. 2003;9:3362–3368.
    1. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008;5:e120.
    1. Bukur J, Loeffler D, Massa C, Mueller L, Riemann D, et al. “Tumor immunology meets oncology IV”, 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany. Cancer Immunol Immunother. 2010;59:955–962.
    1. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther. 2006;5:1136–1144.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit